• Journal of Nutrition and Health
• /
• 제36권8호
• /
• pp.834-840
• /
• 2003

지방간 소견을 나타낸 12인의 피검자를 대상으로 하여 3개월간 1일 2회, 아침과 저녁 식사를 생식으로 대용시킨 후 3개월후 혈액 및 신체계측 조사를 통하여 생식의 지방간 개선 효과를 관찰하였다. 그 결과 생식 섭취 3개월후 체지방 양 및 체중의 감소가 나타났으며, 간손상의 지표로 사용되는 AST, ALT, r-GTP 및 ALP의 활성이 모두 유의적으로 저하되는 모습이 관찰되어 생식의 섭취가 지방간을 개선시키는데 유용한 도구가 될 수 있는 것으로 판명되었다. 생식의 지방간 개선 기작을 탐구하기 위하여 고지방 사료를 통하여 흰 쥐에게 고지혈증을 유도한 이후 생식을 6주간 섭취시킨 결과에서도 실험 동물의 혈중 콜레스테롤, 중성지방의 농도가 모두 낮아지는 것으로 나타나 생식 섭취가 체내지질 대사의 정상화에 기여하는 능력이 있는 것으로 판단되었다. 지방간은 다양한 원인에 의해서 발생되나 그 중 가장 중요한 인자는 체내 높은 지방 함량이라 할 수 있으며, 생식의 섭취는 체내 지질 대사를 정상화함으로서 지방간의 개선에 높은 효과를 발휘 할 수 있을 것으로 추측된다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제23권1호
• /
• pp.89-97
• /
• 2020

Purpose: Obese children may often present with advanced bone age. We aimed to evaluate the correlation between factors associated with childhood obesity and advanced bone age. Methods: We enrolled 232 overweight or obese children. Anthropometric and laboratory data, and the degree of nonalcoholic fatty liver disease (NAFLD) were measured. We analyzed factors associated with advanced bone age by measuring the differences between bone and chronological ages. Results: The normal and advanced bone age groups were comprised of 183 (78.9%) and 49 (21.1%) children, respectively. The prevalence of advanced bone age significantly increased as the percentiles of height, weight, waist circumference, and body mass index (BMI) increased. BMI z-score was higher in the advanced bone age group than in the normal bone age group (2.43±0.52 vs. 2.10±0.46; p<0.001). The levels of insulin (27.80±26.13 μU/mL vs. 18.65±12.33 μU/mL; p=0.034) and homeostatic model assessment-insulin resistance (6.56±6.18 vs. 4.43±2.93; p=0.037) were significantly higher, while high density lipoprotein-cholesterol levels were lower (43.88±9.98 mg/dL vs. 48.95±10.50 mg/dL; p=0.005) in the advanced bone age group compared to those in the normal bone age group, respectively. The prevalence of advanced bone age was higher in obese children with metabolic syndrome than in those without (28.2% vs. 14.7%; p=0.016). The prevalence of advanced bone age was higher in obese children with a more severe degree of NAFLD. Conclusion: Advanced bone age is associated with a severe degree of obesity and its complications.

• 사상체질의학회지
• /
• 제27권1호
• /
• pp.82-109
• /
• 2015

Objectives This research was proposed to present Clinical Practice Guideline (CPG) for Prevention of Sasangin disease pattern of Sasang Constitutional Medicine (SCM) and diseases closely related with Sasang constitution. Each CPG was developed by the national-wide experts committee consisting of SCM professors. Methods At first, we searched the literatures related to SCM such as "Dongeuisusebowon", Textbook of SCM and Clinical Guidebook of SCM. Also we searched the articles related to the studies about risk factors for Sasangin disease pattern of both at home and abroad. Finally, we selected leading risk factors of Sasangin disease pattern and developed CPG for prevention of Sasangin disease pattern of SCM. And then, we searched the literatures related SCM such as "Dongeuisusebowon" and the articles on the correlation between disease and Sasang constitution using case-control studies, observational studies or cross sectional studies of both at home and abroad. Next, we selected diseases closely related with Sasang constitution on the basis of articles including prevalence rate and odds ratio between disease and Sasang constitution and finally developed CPG for these diseases. Results and Conclusions We categorized risk factors of Sasang disease pattern into 2 types: non-modifiable and potentially modifiable. 3 items (age, sex and genetic factors) were classified as non-modifiable risk factors of Sasang disease pattern. 6 items (original symptom, stress, diet and nutrition, physical activity, alcohol and drug misuse) were classified as less well-documented or potentially modifiable risk factors of Sasangin disease pattern. We found out Sasang constitution is more likely to develop some diseases. It was proven that Sasang constitution increase the risk of hypertension, diabetes mellitus, metabolic syndrome, stroke, nonalcoholic fatty liver and obstructive sleep apnea. And there is high probability of Sasang constitution being potential risk factor for obesity, hyperlipidemia, allergy and cancer. Also, we found out Taeeumin is independent risk factor for hypertension, diabetes mellitus, metabolic syndrome, stroke, nonalcoholic fatty liver and obstructive sleep apnea. Therefore we recommend that Taeeumin need to prevent these disease by regular checkups and aggressive management.

• Biomolecules & Therapeutics
• /
• 제29권5호
• /
• pp.455-464
• /
• 2021

Uncontrolled inflammation is considered the pathophysiological basis of many prevalent metabolic disorders, such as nonalcoholic fatty liver disease, diabetes, obesity, and neurodegenerative diseases. The inflammatory response is a self-limiting process that produces a superfamily of chemical mediators, called specialized proresolving mediators (SPMs). SPMs include the ω-3-derived family of molecules, such as resolvins, protectins, and maresins, as well as arachidonic acid-derived (ω-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, and alleviation of pain and promote tissue regeneration via novel mechanisms. SPMs function by binding and activating G protein-coupled receptors, such as FPR2/ALX, GPR32, and ERV1, and nuclear orphan receptors, such as RORα. Recently, several studies reported that SPMs have the potential to attenuate lipid metabolism disorders. However, the understanding of pharmacological aspects of SPMs, including tissue-specific biosynthesis, and specific SPM receptors and signaling pathways, is currently limited. Here, we summarize recent advances in the role of SPMs in resolution of inflammatory diseases with metabolic disorders, such as nonalcoholic fatty liver disease and obesity, obtained from preclinical animal studies. In addition, the known SPM receptors and their intracellular signaling are reviewed as targets of resolution of inflammation, and the currently available information on the therapeutic effects of major SPMs for metabolic disorders is summarized.

• 생명과학회지
• /
• 제32권12호
• /
• pp.962-970
• /
• 2022

비알코올성 지방간염(nonalcoholic steatohepatitis, NASH)은 비알코올성 지방간 질환(nonalcoholic fatty liver disease, NAFLD)의 진행질환으로, 중성지방 침착, 염증 및 간 섬유화가 동반되어 간경변증과 간암의 원인이 되는 질환이나, 아직까지 비알코올성 지방간염을 치료하는 뚜렷한 치료제가 없는 실정이다. Poricoic acid (PoA)는 복령의 약효성분으로 여러 약리작용이 보고되었으나 비알코올성 지방간염의 치료 효능은 보고되지 않았다. 따라서 본 연구에서는 PoA가 비알코올성 지방간염의 병인에 작용하여 비알코올성 지방간염을 억제하는지를 in vivo 및 in vitro 연구를 통해 확인하였다. 비알코올성 지방간염을 유도하는 식이(high fat and methionine-choline deficient diet, HFMCD)로 비알코올성 지방간염을 유발한 쥐에서 PoA는 HFMCD에 의해 증가된 간 무게를 감소시켰으며, 간 독성을 나타내는 alanine aminotransferase, aspartate aminotransferase도 감소시켰다. Oil Red O 염색 및 hematoxylin & eosin 염색의 결과에 의하면, PoA는 HFMCD에 증가하는 간 조직 내 중성지방의 생성을 감소시켰으며, qPCR 결과에 의해서도 PoA는 중성 지방 합성과 관련된 유전자들의 발현도 감소시켰다. 또한 간 조직에서 CD68 면역 염색 결과에 의하면, PoA는 HFMCD에 의해 증가는 CD68 면역 염색을 감소시켰으며, 염증과 관련된 유전자 발현도 감소시켰다. 더욱이 Sirius red 염색과 α-smooth muscle actin (α-SMA) 면역 염색으로 간 섬유화 정도를 측정한 결과, PoA는 HFMCD에 증가되는 sirius red 염색과 α-SMA 면역 염색을 유의적으로 감소시켰으며 섬유화 관련 유전자들의 발현도 감소시켰다. 또한, PoA는 palmitate (Pa)로 처리한 간세포 AML12에서 Pa에 의해 증가하는 중성 지방산 합성, 염증 및 섬유화 관련 유전자들의 발현을 감소시켰다. 이상의 결과를 종합하면 PoA는 비알코올성 지방간염의 중요 병인인 중성지방 생성, 염증 및 섬유화를 억제하여 비알코올성 지방간염을 억제함을 확인하였다.

• 한국건강관리협회지
• /
• 제3권2호
• /
• pp.121-136
• /
• 2005

Background/Aims The liver funtion tests(LFTs), such as aspartate aminotransferase(AST), alanine amino-transferase(ALT), r -glutamyl transferase( r -GT), have been widely used for screening tests but their low positive predictive value can cause many false positive results. To evaluate the clinical usefulness of these tests, we analyzed serial LFT results of single factory workers and compared the risk factor's in groups divided by the serial LFT results. Methods From June 2001 to October 2001, 1223 consecutive healthy workers in a single factory were enrolled and questionnaire, LFT and liver ultrasonography were performed. Previous LFT results were collected from Annual Health Examination Survey. According to the abnormalities in serial LFT, participants were classified into three groups (abnormal-in-both, alternating normal-in-both) and the risk factors were compared among these groups using multiple logistic regression Results The prevalence of LFT abnormality in a single test was 16.8% but, in serial LFT, only 5% of participants showed consistent abnormality. The risk factors for abnormal-in-both group, compared with alternating group, were liver ultrasonography abnormality such as fatty liver(odds ratio, 2.2; p=0.026) and heavy alcohol intake (more than 210g/week) (odds ratio, 7.2;P=0.064). HBsAg was not significant risk factor for any of the three groups. ConclusionIn factory workers with serial LFT abnormality, alcoholic liver disease could be the principal cause of abnormal LFT. Even if HBsAg were positive in patients with abnormal LFT, there is a possibility of another causes for LFT abnormalities such as alcoholic liver disease and nonalcoholic steatosis or steatohepatitis

• 한국동물위생학회지
• /
• 제36권1호
• /
• pp.45-52
• /
• 2013

The purpose of the present study is to determine whether Schisandra chinensis (SC) has a protective effect on high fat diet (HFD)-induced fatty liver including hepatic lipid accumulation in rats. The HFD-induced obese rats were weighed after SC extracts were administered through the gastrointestinal tract at a concentration of 250 mg/kg b.w/day for 5 weeks. After 5 weeks, all of the rats on a high fat-diet were 36.5% heavier compared with normal controls. In contrast, rats on a high-fat diet supplemented with SC were 23.5% lighter than rats fed only a high-fat diet. Although there was no significant difference in food intake among the groups during the experimental diet period, the body weight gain of the SC group was significantly lower than the weights of the HFD groups. SC treatment slightly decreased the liver weight. Reduction of hepatic TBARS contents by SC was observed in rats fed a diet containing SC, and antioxidant activity was markedly increased in HFD＋SC group compared to those of HFD group in liver. Moreover, total-lipid and triglyceride contents in the liver of groups fed a diet containing SC were significantly lower compared to those of the HFD group. High fat feeding elevated liver cholesterol concentration, but the addition of SC to the HFD rats resulted in the significant decrease in liver cholesterol. In histological observation of liver tissues, the hepatocytes of HFD rats showed a typical fatty liver morphology showing numerous lipid droplets in cytoplasm, whereas administration of SC reduced the size and numbers of lipid droplets. These results clearly demonstrated the attenuation of SC on nonalcoholic fatty liver induced by obese rats fed HFD.

• Clinical and Experimental Pediatrics
• /
• 제48권3호
• /
• pp.276-283
• /
• 2005

목 적 : 내장 지방은 비만 합병증의 위험 인자이며 성인에서 지방간은 내장 지방과 관련이 있음이 알려져 있다. 소아 비만의 진단기준인 BMI가 내장 지방 정도를 반영하는지를 살펴보고 소아 지방간 환아에서 BMI, 체지방 분포, 간 효소치와 복부 CT상 지방간 정도 사이의 상관관계를 알아보고자 하였다. 방 법 : 2000년 1월부터 2004년 2월까지 BMI를 기준으로 비만위험 또는 비만에 동반된 간 효소치 이상을 주소로 서울대학교 어린이병원 소아과에 내원하여 비조영증강 복부 CT 검사로 지방간을 진단받은 소아 23례(남아 19명, 여아 4명)를 대상으로 하여 CT로 복부 지방 면적을 측정하였다. BMI와 내장 지방과의 상관관계, 복부 CT상 지방간의 정도와 BMI, VAT, VSR, 간 효소치간의 상관관계를 분석하였다. 결 과 : BMI는 TAF(r=0.91476, P<0.0001), VAT(r=0.51719, P=0.0115), SAAT(r=0.88302, P<0.0001)와 유의한 상관관계가 있었다. CTL/CTS비와 BMI(r=-0.11938, P=0.5876), TAF(r=-0.14936, P=0.4964), VAT(r=-0.31234, P=0.1468), SAAT(r=-0.08154, P=0.7115), VSR(r=-0.19202, P=0.3801), AST(r=0.12729, P=0.5628), ALT(r=-0.00179, P=0.9935) 및 AST/ALT비(r=0.20762, P=0.3418) 사이에 유의한 상관관계가 없었다. 결 론 : 소아 비만에서 BMI는 내장 지방 정도를 반영하나 복부 CT상 지방간의 정도와 간 효소치, BMI, 내장 지방량 사이에 유의한 상관관계가 없었다.

• Biomolecules & Therapeutics
• /
• 제31권1호
• /
• pp.40-47
• /
• 2023

Activation of the NLRP3 inflammasome is a necessary process to induce fibrosis in nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH) is a kind of NAFLD that encompasses the spectrum of liver disease. It is characterized by inflammation and ballooning of hepatocytes during steatosis. We tested whether inhibiting the NLRP3 inflammasome could prevent the development and pathology of NASH. We identified loganin as an inhibitor of the NLRP3 inflammasome and investigated whether in vivo administration of loganin prevented NASH symptoms using a methionine-choline deficient (MCD) diet model in mice. We found that loganin inhibited the NLRP3 inflammasome activation triggered by ATP or nigericin, as shown by suppression of the production of interleukin (IL)-1β and caspase-1 (p10) in mouse primary macrophages. The speck formation of apoptosisassociated speck-like protein containing a caspase recruitment domain (ASC) was blocked by loganin, showing that the assembly of the NLRP3 inflammasome complex was impaired by loganin. Administration of loganin reduced the clinical signs of NASH in mice fed the MCD diet, including hepatic inflammation, fat accumulation, and fibrosis. In addition, loganin reduced the expression of NLRP3 inflammasome components in the liver. Our findings indicate that loganin alleviates the inflammatory symptoms associated with NASH, presumably by inhibiting NLRP3 inflammasome activation. In summary, these findings imply that loganin may be a novel nutritional and therapeutic treatment for NASH-related inflammation.

• The Korean Journal of Physiology and Pharmacology
• /
• 제18권4호
• /
• pp.333-339
• /
• 2014

Exendin-4 (Ex-4), a glucagon-like peptide-1 receptor (GLP-1R) agonist, has been known to reverse hepatic steatosis in ob/ob mice. Although many studies have evaluated molecular targets of Ex-4, its mechanism of action on hepatic steatosis and fibrosis has not fully been determined. In the liver, glucose transporter 4 (GLUT4) is mainly expressed in hepatocytes, endothelial cells and hepatic stellate cells (HSCs). In the present study, the effects of Ex-4 on GLUT4 expression were determined in the liver of ob/ob mice. Ob/ob mice were treated with Ex-4 for 10 weeks. Serum metabolic parameters, hepatic triglyceride levels, and liver tissues were evaluated for hepatic steatosis. The weights of the whole body and liver in ob/ob mice were reduced by long-term Ex-4 treatment. Serum metabolic parameters, hepatic steatosis, and hepatic fibrosis in ob/ob mice were reduced by Ex-4. Particularly, Ex-4 improved hepatic steatosis by enhancing GLUT4 via GLP-1R activation in ob/ob mice. Ex-4 treatment also inhibited hepatic fibrosis by decreasing expression of connective tissue growth factor in HSCs of ob/ob mice. Our data suggest that GLP-1 agonists exert a protective effect on hepatic steatosis and fibrosis in obesity and type 2 diabetes.